Особенности лечения нарушений ритма сердца у пациентов с хронической сердечной недостаточностью
https://doi.org/ 10.18087/cardio.2391
Аннотация
Представлен обзор данных, касающихся особенностей лечения нарушений ритма сердца у пациентов с ХСН. Обсуждаются эффективность и безопасность антиаритмических препаратов, высокая частота проаритмических эффектов. Показано, что при выборе антиаритмических препаратов определяющее значение имеют основное заболевание пациента и тяжесть структурных повреждений сердца. Обсуждается лечение желудочковых аритмий и фибрилляции предсердий.
Список литературы
1. Кэмм А. Дж., Люшер Т. Ф., Серриус П. В., под ред. Шляхто Е. В. Руководство Европейского общества кардиологов. Болезни сердца и сосудов. Желудочковая тахикардия и внезапная сердечная смерть. Гл. 30. Перевод с англ. -М.: ГЭОТАР-Медиа; 2011. 1480 с
2. Estrada JC, Darbar D. Clinical use of and future perspectives on anti-arrhythmic drugs. Eur J. Clin Pharmacol. 2008;64 (12):1139-46. DOI:10.1007/s00228-008-0555-x.
3. Mozaffarian D., Anker SD, Anand I., Linker DT, Sullivan MD, Cleland JGF et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation. 2007;116 (4):392-8. DOI:10.1161 /CIRCULATIONAHA. 106.687103.
4. Jhund PS, Fu M., Bayram E., Chen C-H, Negrusz-Kawecka M., Rosenthal A. et al. Efficacy and safety of LCZ696 (sacubitril-val-sartan) according to age: insights from PARA.DIGM-HF. European Heart Journal. 2015;36 (38):2576-84. DOI:10.1093/eurheartj/ehv330.
5. Рекомендации ESC по лечению пациентов с желудочковыми нарушениями ритма и профилактике внезапной сердечной смерти 2015. Российский Кардиологический Журнал. 2016; (7 (135)): 5-86
6. Francia P, Palano F, Tocci G, Adduci C, Ricotta A, Semprini L et al. Angiotensin receptor antagonists to prevent sudden death in heart failure: does the dose matter? ISRN Cardiol. 2014;2014:652421. DOI:10.1155/2014/652421.
7. Frommeyer G, Eckardt L. Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol. 2016;13 (1):36-47. DOI:10.1038/nrcardio.2015.110.
8. Коваленко В. Н., редактор. Руководство по кардиологии. Часть 1. -Киев: МОРИОН; 2008. 1424 с
9. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace. 2011;13 (3):329-45. DOI: 10.1093 /europace/euq450.
10. Фогорос Р. Н. Антиаритмические средства. Изд. 2-е. Пер. с англ, под ред. проф. Ю. М. Позднякова, А. В. Тарасова. -М.: Издательство БИНОМ; 2009. 200 с
11. Cubeddu LX. Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias. Curr Cardiol Rev. 2016;12 (2):141-54.
12. Al-Gobari M, El Khatib C, Pillon F, Gueyffier F. β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2013; 13:52. DOI: 10.1186/1471-2261-13-52.
13. Le H-H, El-Khatib C, Mombled M, Guitarian F, Al-Gobari M, Fall M et al. Impact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE. 2016;11 (2):e0145958. DOI: 10.1371 /journal.pone.0145958.
14. Torp-Pedersen C, Metra M, Spark P, Lukas MA, Moullet C, Scherhag A et al. The safety of amiodarone in patients with heart failure. J Card Fail. 2007;13 (5):340-5. DOI:10.1016/j.card-fail.2007.02.009.
15. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352 (3):225-37. DOI: 10.1056/NEJMoa043399.
16. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354: i4482.
17. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J. 2015;36 (46):3250-7. DOI:10.1093/eurheartj/ehv513.
18. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37 (38):2893-962. DOI:10.1093/eurheartj/ehw210.
19. Steinberg BA, Broderick SH, Lopes RD, Shaw LK, Thomas KL, DeWald TA et al. Use of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease. Europace. 2014;16 (9):1284-90. DOI: 10.1093/europace/euu077.
20. Flaker G, Lopes RD, Hylek E, Wojdyla DM, Thomas L, Al-Khatib SM et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol. 2014;64 (15):1541-50. DOI:10.1016/ j.jacc.2014.07.967.
21. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H-C, Hacke W et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J. 2016; DOI:10.1093/eurheartj/ehw058.
22. Allen LaPointe NM, Lokhnygina Y, Sanders GD, Peterson ED, Al-Khatib SM. Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation. Am Heart J. 2013;166 (5):871-8. DOI: 10.1016/j.ahj.2013.08.010
23. Qin D, Leef G, Alam MB, Rattan R, Munir MB, Patel D et al. Mortality risk of long-term amiodarone therapy for atrial fibrillation patients without structural heart disease. Cardiol J. 2015;22 (6):622-9. DOI: 10.5603/CJ.a2015.0055
24. Qin D, Leef G, Alam MB, Rattan R, Munir MB, Patel D et al. Patient outcomes according to adherence to treatment guidelines for rhythm control of atrial fibrillation. J Am Heart Assoc. 2015;4 (4). DOI: 10.1161/JAHA.115.001793.
25. Nielsen PB, Larsen TB, Gorst-Rasmussen A, Skjoth F, Lip GYH. β-Blockers in Atrial Fibrillation Patients With or Without Heart Failure: Association With Mortality in a Nationwide Cohort Study. Circ Heart Fail. 2016;9 (2):e002597. DOI:10.1161 /CIRCHEART FAILURE.115.002597.
26. Mareev Y, Cleland JGF. Should ß-blockers be used in patients with heart failure and atrial fibrillation? Clin Ther. 2015;37 (10):2215-24. DOI: 10.1016/j.clinthera.2015.08.017.
27. Cullington D, Goode KM, Zhang J, Cleland JGF, Clark AL. Is Heart Rate Important for Patients With Heart Failure in Atrial Fibrillation? JACC: Heart Failure. 2014;2 (3):213-20. DOI:10.1016/j.jchf.2014.01.005.
28. Lu HT, Kam J, Nordin RB, Khelae SK, Wang JM, Choy CN et al. Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study. J Geriatr Cardiol. 2016;13 (9):749 59. D0I:10.11909/j.issn. 1671-5411.2016.09.009
29. Simpson J, Castagno D, Doughty RN, Poppe KK, Earle N, Squire I et al. Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. Eur J Heart Fail. 2015;17 (11):1182-91. D0I:10.1002/ejhf.346.
30. Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual 0utcomes. 2013;6 (5):525-33. D0I:10.1161/CIRC0UTC0MES.111.000079.
31. Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullal AJ, Than CT et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREATAF study. J Am Coll Cardiol. 2014;64 (7):660-8. D0I:10.1016/ j.jacc.2014.03.060.
32. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015;36 (28): 1831-8. D01:10.1093/eurheartj/ehv143.
33. Holmqvist F, Stridh M, Waktare JEP, Sörnmo L, Ølsson SB, Meurling CJ. Atrial fibrillatory rate and sinus rhythm maintenance in patients undergoing cardioversion of persistent atrial fibrillation. Eur Heart J. 2006;27 (18):2201-7. D0I:10.1093/eurheartj/ehl098.
34. Chen Y, Cai X, Huang W, Wu Y, Huang Y, Hu Y. Increased All-Cause Mortality Associated With Digoxin Therapy in Patients With Atrial Fibrillation: An Updated Meta-Analysis. Medicine (Baltimore). 2015;94 (52):e2409. D0I:10.1097/MD.0000000000002409.
35. Zeng W-T, Liu Z-H, Li Z-Y, Zhang M, Cheng Y-J. Digoxin Use and Adverse 0utcomes in Patients With Atrial Fibrillation. Medicine (Baltimore). 2016;95 (12):e2949. D0I:10.1097/MD.000000000 0002949.
36. Zipes DP, Jalife J, editors. Cardiac electrophysiology: from cell to bedside. Sixth edition. -Philadelphia, PA: Elsevier/Saunders; 2014. 1365 p.
37. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation. 1999;99 (4):552-7.
38. Hohnloser SH, Halperin JL, Camm AJ, Gao P, Radzik D, Connolly SJ et al. Interaction between digoxin and dronedarone in the PALLAS trial. Circ Arrhythm Electrophysiol. 2014;7 (6):1019-25. D0I:10. 1161/CIRCEP.114.002046.
Рецензия
Для цитирования:
Тарловская Е.И. Особенности лечения нарушений ритма сердца у пациентов с хронической сердечной недостаточностью. Кардиология. 2017;57(1S):323-332. https://doi.org/ 10.18087/cardio.2391
For citation:
Tarlovskaya E.I. Peculiarities of therapy for heart rhythm disorders in patients with chronic heart failure. Kardiologiia. 2017;57(1S):323-332. (In Russ.) https://doi.org/ 10.18087/cardio.2391
Просмотров: 575
Послать статью по эл. почте 
Оставить комментарий 